Control of the lentiviral vector vaccination field
due to a broad & solid intellectual property position
The Pasteur Institute has built a broad and strong patent portfolio covering the use of any gene tranfer vector incorporating the DNA flap sequence. Through our R&D activities and breackthrough discoveries, we have further expanded our IP leading position in lentiviral vectors for both human & veterinary vaccination applications.
In 2007, THERAVECTYS & The Pasteur Institute have executed a worldwide exclusive IP licensing agreement covering the use and the production of lentiviral vectors for vaccination applications
Prophylactic & therapeutic human & veterinary vaccination applications:
in infectious diseases, parasitic diseases, viro-induced cancers, cancers...
Production & commercialization
of GMP clinical material.